Determinants of graft survival after renal transplantation

Transplantation

Volumn 61, Issue 11, 1996, Pages 1581-1586

  Pirsch, John D ^a,b   Ploeg, Rutger J ^a   Gange, Stephen ^a   D'Alessandro, Anthony M ^a   Knechtle, Stuart J ^a   Sollinger, Hans W ^a   Kalayoglu, Munci ^a   Belzer, Folkert O ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA 2 MICROGLOBULIN; BLOOD GROUP B ANTIGEN; CORTICOSTEROID; CREATININE; CYCLOSPORIN; HLA DR ANTIGEN; LYMPHOCYTE ANTIBODY; NITROGEN; OKT 3; PREDNISONE; STEROID; THYMOCYTE ANTIBODY; UREA;

ADULT; AGE; ARTICLE; CADAVER KIDNEY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; CADAVER; FEMALE; GRAFT SURVIVAL; HLA-DR ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 0029942218     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199606150-00006     Document Type: Article

References (31)

1. European Multicentre Trial. Cyclosporin A as sole immunosuppressive agent in recipients of kidney allografts from cadaver donors. Lancet 1982; 2: 57.
2. Canadian Multicentre Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation: analysis at three years. N Engl J Med 1986; 314: 1219.
3. Ferguson RM, Rynasiewicz JJ, Sutherland DER, Simmons RL, Najarian JS. Cyclosporin A in renal transplantation: a prospective randomized trial. Surgery 1982; 92: 175.
4. Cosimi AB, Burton RC, Colvin RB, et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 1981; 32: 535.
5. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985; 313: 337.
6. Gjertson DW. Survival trends in long-term first cadaver-donor kidney transplants. In: Terasaki P, ed. Clinical transplants 1991. Los Angeles: UCLA Tissue Typing Laboratory, 1992: 225.
7. Matas AJ, Sutherland DER, Najarian JS. The impact of HLA matching on graft survival. Transplantation 1992; 54: 568.
8. Tesi RJ, Henry ML, Elkhammas EA, Ferguson RM. Predictors of long-term primary cadaveric renal transplant survival. Clin Transpl 1993; 7: 345.
9. Gjertson DW: Short- and long-term effects of HLA matching. In: Terasaki P, ed. Clinical Transplants 1989. Los Angeles: UCLA Tissue Typing Laboratory, 1989: 353.
10. Opelz G, Schwarz V, Engelmann A, Back D, Wilk M, Keppel E. Long-term impact of HLA matching on kidney graft survival in cyclosporine-treated recipients. Transplant Proc 1991; 23: 373.
11. Takemoto S, Terasaki PI, Cecka JM, Cho YW, Gjertson DW, for the UNOS Scientific Renal Transplant Registry. Survival of nationally shared, HLA-matched kidney transplants from cadaveric donors. N Engl J Med 1992; 327: 834.
12. U.S. Department of Health and Human Services, Public Health Service, Health Resources and Services Administration. Kidney data: 1991 report of center-specific graft and patient survival rates. Washington, DC: USDHHS, 1991.
13. Ogura K, Cecka JM. Center effects in renal transplantation. In: Terasaki P, ed. Clinical transplants 1991. Los Angeles: UCLA Tissue Typing Laboratory, 1992; 245.
14. Terasaki PI, Cecka JM, Lim E, et al. Overview. In: Terasaki P, ed. Clinical transplants 1991. Los Angeles: UCLA Tissue Typing Laboratory, 1992: 409.
15. Ploeg RJ, Van Bockel JH, Langendijk PTH, et al. for the European Multicentre Study Group. Effect of preservation solution on results of cadaveric kidney transplantation. Lancet 1992; 340: 129.
16. Salomon DR. Cyclosporine nephrotoxicity and long-term renal transplantation. Transplant Rev 1992; 6: 10.
17. Amend W, Soskin T, Vincenti F, et al. Long-term experience in primary cadaver renal transplants using cyclosporine. Clin Transpl 1990; 4: 341.
18. Fischel RJ, Payne WD, Gillingham KJ, et al. Long-term outlook for renal transplant recipients with one-year function: "doctor, what are my chances?" Transplantation 1991; 51: 118.
19. D'Alessandro AM, Lorentzen DF, Pirsch JD, et al. Cadaveric renal transplantation in the cyclosporine and OKT3 eras: an update of the University of Wisconsin-Madison experience. In: Terasaki P, ed. Clinical transplants 1989. Los Angeles: UCLA Tissue Typing Laboratory, 1989: 239.
20. Hong JH, Sumrani N, Delaney V, Davis R, Dibenedetto A, Butt KMH. Causes of late renal allograft failure in the ciclosporin era. Nephron 1992; 62: 272.
21. Bergmann LS, Roper L, Bow LM, Hull D, Bartus SA, Schweizer RT. Causes of late graft failure in cadaveric renal transplantation. Transplant Proc 1993; 25: 1340.
22. Schweizer RT, Rovelli M, Palmeri D, Vossler E, Hull D, Bartus S. Noncompliance in organ transplant recipients. Transplantation 1990; 49: 374.
23. Dunn J, Golden D, Van Buren CT, Lewis RM, Lawen J, Kahan BD. Causes of graft loss beyond two years in the cyclosporine era. Transplantation 1990; 49: 349.
24. Cicciarelli J, Iwaki Y, Mendez R, et al. Effects of cold ischemia time on cadaver renal allografts. Transplant Proc 1993; 25: 1543.
25. Wrenshall LE, Matas AJ, Canafax DM, et al. An increased incidence of late acute rejection episodes in cadaver renal allograft recipients given azathioprine, cyclosporine, and prednisone. Transplantation 1990; 50: 233.
26. Salomon DR. An alternative view minimizing the significance of cyclosporine nephrotoxicity and in favor of enhanced immunosuppression for long-term kidney transplant recipients. Transplant Proc 1991; 23: 2115.
27. Sanders CE, Curtis JJ, Julian BA, et al. Tapering or discontinuing cyclosporine for financial reasons: a single-center experience. Am J Kidney Dis 1993; 21: 9.
28. Matas AJ, Brayman KL, Gillingham KJ. Presentation of renal transplant graft survival data: where should "death with a functioning graft" be included? Clin Transpl 1990; 4: 142.
29. Cecka JM, Cho YW, Terasaki PI. Analyses of the UNOS scientific renal transplant registry at three years: early events affecting transplant success. Transplantation 1992; 53: 59.
30. Hoffmann RM, Stratta RJ, D'Alessandro AM, et al. Combined cold storage-perfusion preservation with a new synthetic perfusate. Transplantation 1989; 47: 32.
31. Dawidson I, Rooth P, Alway C, et al. Verapamil prevents post-transplant delayed function and cyclosporine A nephrotoxicity. Transplant Proc 1990; 22: 1379.